Table 5

Multivariate analysis of risk factors possibly associated with post-transplantation complications in a cohort of 194 patients treated by HCT

Variable/groupRelative risk of complications95% CIP
Year    
    Up to 1999 1.00   
    Since 2000 0.66 0.39-1.13 .130 
Age, y    
     Younger than 2 1.00   
    2-5 1.53 0.90-2.58 .115 
    Older than 5 1.39 0.78-2.45 .262 
Clinical score    
     < 3 1.00   
    3 or 4 1.26 0.57-2.78 .574 
    5 1.30 0.56-3.01 .543 
Cell source    
    BM 1.00   
    PBSCs 1.45 0.69-3.04 .324 
    UCB 0.95 0.12-7.48 .960 
Donor    
    MSD 1.00   
    MMFD 2.45 1.15-5.20 .019 
    MFD 1.41 0.30-6.58 .662 
    URD 1.56 0.77-3.17 .219 
    UCB 5.18 0.60-42.0 .124 
Conditioning    
    Myeloablative 1.00   
    Reduced-intensity 1.80 0.97-3.31 .060 
Variable/groupRelative risk of complications95% CIP
Year    
    Up to 1999 1.00   
    Since 2000 0.66 0.39-1.13 .130 
Age, y    
     Younger than 2 1.00   
    2-5 1.53 0.90-2.58 .115 
    Older than 5 1.39 0.78-2.45 .262 
Clinical score    
     < 3 1.00   
    3 or 4 1.26 0.57-2.78 .574 
    5 1.30 0.56-3.01 .543 
Cell source    
    BM 1.00   
    PBSCs 1.45 0.69-3.04 .324 
    UCB 0.95 0.12-7.48 .960 
Donor    
    MSD 1.00   
    MMFD 2.45 1.15-5.20 .019 
    MFD 1.41 0.30-6.58 .662 
    URD 1.56 0.77-3.17 .219 
    UCB 5.18 0.60-42.0 .124 
Conditioning    
    Myeloablative 1.00   
    Reduced-intensity 1.80 0.97-3.31 .060 

BM indicates bone marrow; and PBSCs, peripheral blood stem cells.

Close Modal

or Create an Account

Close Modal
Close Modal